These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

417 related articles for article (PubMed ID: 32862455)

  • 1. A high TP53 mutation burden is a strong predictor of primary refractory mantle cell lymphoma.
    Obr A; Klener P; Furst T; Kriegova E; Zemanova Z; Urbankova H; Jirkuvova A; Petrackova A; Malarikova D; Forsterova K; Cudova B; Sedlarikova L; Berkova A; Kasalova N; Papajik T; Trneny M
    Br J Haematol; 2020 Dec; 191(5):e103-e106. PubMed ID: 32862455
    [No Abstract]   [Full Text] [Related]  

  • 2. Complex analysis of the TP53 tumor suppressor in mantle cell and diffuse large B-cell lymphomas.
    Zlamalikova L; Moulis M; Ravcukova B; Liskova K; Malcikova J; Salek D; Jarkovsky J; Svitakova M; Hrabalkova R; Smarda J; Smardova J
    Oncol Rep; 2017 Oct; 38(4):2535-2542. PubMed ID: 28791403
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Frontline bortezomib, rituximab, cyclophosphamide, doxorubicin, and prednisone (VR-CAP) versus rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in transplantation-ineligible patients with newly diagnosed mantle cell lymphoma: final overall survival results of a randomised, open-label, phase 3 study.
    Robak T; Jin J; Pylypenko H; Verhoef G; Siritanaratkul N; Drach J; Raderer M; Mayer J; Pereira J; Tumyan G; Okamoto R; Nakahara S; Hu P; Appiani C; Nemat S; Cavalli F;
    Lancet Oncol; 2018 Nov; 19(11):1449-1458. PubMed ID: 30348538
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lenalidomide plus bendamustine-rituximab does not overcome the adverse impact of
    Eskelund CW; Albertsson-Lindblad A; Kolstad A; Laurell A; Räty R; Pedersen LB; Geisler CH; Jerkeman M; Grønbæk K
    Haematologica; 2018 Nov; 103(11):e541-e543. PubMed ID: 29794145
    [No Abstract]   [Full Text] [Related]  

  • 5. Bortezomib plus CHOP-rituximab for previously untreated diffuse large B-cell lymphoma and mantle cell lymphoma.
    Ruan J; Martin P; Furman RR; Lee SM; Cheung K; Vose JM; Lacasce A; Morrison J; Elstrom R; Ely S; Chadburn A; Cesarman E; Coleman M; Leonard JP
    J Clin Oncol; 2011 Feb; 29(6):690-7. PubMed ID: 21189393
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bendamustine, vincristine and prednisone (BOP) versus cyclophosphamide, vincristine and prednisone (COP) in advanced indolent non-Hodgkin's lymphoma and mantle cell lymphoma: results of a randomised phase III trial (OSHO# 19).
    Herold M; Schulze A; Niederwieser D; Franke A; Fricke HJ; Richter P; Freund M; Ismer B; Dachselt K; Boewer C; Schirmer V; Weniger J; Pasold R; Winkelmann C; Klinkenstein C; Schulze M; Arzberger H; Bremer K; Hahnfeld S; Schwarzer A; Müller C; Müller C;
    J Cancer Res Clin Oncol; 2006 Feb; 132(2):105-12. PubMed ID: 16088404
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle-cell lymphoma: results of a prospective randomized trial of the European MCL Network.
    Dreyling M; Lenz G; Hoster E; Van Hoof A; Gisselbrecht C; Schmits R; Metzner B; Truemper L; Reiser M; Steinhauer H; Boiron JM; Boogaerts MA; Aldaoud A; Silingardi V; Kluin-Nelemans HC; Hasford J; Parwaresch R; Unterhalt M; Hiddemann W
    Blood; 2005 Apr; 105(7):2677-84. PubMed ID: 15591112
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lenalidomide maintenance after autologous haematopoietic stem-cell transplantation in mantle cell lymphoma: results of a Fondazione Italiana Linfomi (FIL) multicentre, randomised, phase 3 trial.
    Ladetto M; Cortelazzo S; Ferrero S; Evangelista A; Mian M; Tavarozzi R; Zanni M; Cavallo F; Di Rocco A; Stefoni V; Pagani C; Re A; Chiappella A; Balzarotti M; Zilioli VR; Gomes da Silva M; Arcaini L; Molinari AL; Ballerini F; Ferreri AJM; Puccini B; Benedetti F; Stefani PM; Narni F; Casaroli I; Stelitano C; Ciccone G; Vitolo U; Martelli M
    Lancet Haematol; 2021 Jan; 8(1):e34-e44. PubMed ID: 33357480
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Recent progress in the therapeutic strategy for follicular lymphoma and mantle cell lymphoma].
    Ogura M
    Rinsho Ketsueki; 2006 Jun; 47(6):495-512. PubMed ID: 16862978
    [No Abstract]   [Full Text] [Related]  

  • 10. High-dose therapy with autologous stem cell transplantation in first response in mantle cell lymphoma.
    Vigouroux S; Gaillard F; Moreau P; Harousseau JL; Milpied N
    Haematologica; 2005 Nov; 90(11):1580-2. PubMed ID: 16266909
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial.
    Rummel MJ; Niederle N; Maschmeyer G; Banat GA; von Grünhagen U; Losem C; Kofahl-Krause D; Heil G; Welslau M; Balser C; Kaiser U; Weidmann E; Dürk H; Ballo H; Stauch M; Roller F; Barth J; Hoelzer D; Hinke A; Brugger W;
    Lancet; 2013 Apr; 381(9873):1203-10. PubMed ID: 23433739
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lymphomatous polyposis as primary manifestation of mantle cell lymphoma.
    Yu SC; Liu KL; Chang LC
    Eur J Haematol; 2012 Aug; 89(2):185-6. PubMed ID: 22563740
    [No Abstract]   [Full Text] [Related]  

  • 13. [Clinical analysis of 140 cases of mantle cell lymphoma].
    Hu MW; Lou YJ; Yang M; Wang HF; Wang L; Jin J
    Zhonghua Zhong Liu Za Zhi; 2018 May; 40(5):390-395. PubMed ID: 29860768
    [No Abstract]   [Full Text] [Related]  

  • 14. R-hyper-CVAD versus R-CHOP/cytarabine with high-dose therapy and autologous haematopoietic stem cell support in fit patients with mantle cell lymphoma: 20 years of single-center experience.
    Widmer F; Balabanov S; Soldini D; Samaras P; Gerber B; Manz MG; Goede JS
    Ann Hematol; 2018 Feb; 97(2):277-287. PubMed ID: 29147847
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rituximab-EPOCH, an effective salvage therapy for relapsed, refractory or transformed B-cell lymphomas: results of a phase II study.
    Jermann M; Jost LM; Taverna Ch; Jacky E; Honegger HP; Betticher DC; Egli F; Kroner T; Stahel RA
    Ann Oncol; 2004 Mar; 15(3):511-6. PubMed ID: 14998858
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase 2 trial of bortezomib in combination with rituximab plus hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with bortezomib, rituximab, methotrexate, and cytarabine for untreated mantle cell lymphoma.
    Romaguera JE; Wang M; Feng L; Fayad LE; Hagemeister F; McLaughlin P; Rodriguez MA; Fanale M; Orlowski R; Kwak LW; Neelapu S; Oki Y; Pro B; Younes A; Samaniego F; Fowler N; Hartig K; Valentinetti M; Smith J; Ford P; Naig A; Medeiros LJ; Kantarjian HM; Goy A
    Cancer; 2018 Jun; 124(12):2561-2569. PubMed ID: 29723393
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hyperfractionated Cyclophosphamide, Vincristine, Doxorubicin, and Dexamethasone Chemotherapy in Mantle Cell Lymphoma Patients Is Associated with Higher Rates of Hematopoietic Progenitor Cell Mobilization Failure despite Plerixafor Rescue.
    Salhotra A; Shan Y; Tsai NC; Sanchez JF; Aldoss I; Ali H; Paris T; Spielberger R; Cao TM; Nademanee A; Forman SJ; Chen R
    Biol Blood Marrow Transplant; 2017 Aug; 23(8):1264-1268. PubMed ID: 28434928
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sequential chemotherapy regimens followed by high-dose therapy with stem cell transplantation in mantle cell lymphoma: an update of a prospective study.
    Lefrère F; Delmer A; Levy V; Delarue R; Varet B; Hermine O
    Haematologica; 2004 Oct; 89(10):1275-6. PubMed ID: 15477221
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rituximab and CHOP induction therapy for newly diagnosed mantle-cell lymphoma: molecular complete responses are not predictive of progression-free survival.
    Howard OM; Gribben JG; Neuberg DS; Grossbard M; Poor C; Janicek MJ; Shipp MA
    J Clin Oncol; 2002 Mar; 20(5):1288-94. PubMed ID: 11870171
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mantle cell lymphoma: a great masquerader.
    Paludo J; Kapoor P; Oliveira JL; Garrity JA; Nowakowski GS
    Int J Hematol; 2014 Oct; 100(4):313-4. PubMed ID: 25073863
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 21.